Company / R&D Expense
ACCENDRA HEALTH INC/VA/ R&D Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$13.0M
FY2024
5-year range
$12.0M / $13.0M
FY2022-FY2024
Trend
+0.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense remained relatively stable over the past 3 years, with values between $12M and $13M.
Based on SEC 10-K filings.
$13M in FY2024.
Improved from $12M to $13M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, r&d expense increased 0.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.60 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $13.0M | +0.0% |
| FY2023 | $13.0M | +8.3% |
| FY2022 | $12.0M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026